JP3391796B2 - 新規化合物、その製法および抗腫瘍剤 - Google Patents

新規化合物、その製法および抗腫瘍剤

Info

Publication number
JP3391796B2
JP3391796B2 JP50192396A JP50192396A JP3391796B2 JP 3391796 B2 JP3391796 B2 JP 3391796B2 JP 50192396 A JP50192396 A JP 50192396A JP 50192396 A JP50192396 A JP 50192396A JP 3391796 B2 JP3391796 B2 JP 3391796B2
Authority
JP
Japan
Prior art keywords
group
compound
hydrogen atom
halogen atom
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP50192396A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO1995034559A1 (ja
Inventor
恭司 冨田
勝巳 千葉
茂樹 柏本
厚一郎 柴森
保知 筑木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Publication of JPWO1995034559A1 publication Critical patent/JPWO1995034559A1/ja
Application granted granted Critical
Publication of JP3391796B2 publication Critical patent/JP3391796B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP50192396A 1994-06-14 1995-06-06 新規化合物、その製法および抗腫瘍剤 Expired - Lifetime JP3391796B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
JP6-156578 1994-06-14
JP15657894 1994-06-14
JP19792194 1994-07-28
JP6-197921 1994-07-28
JP6-306914 1994-11-15
JP30691494 1994-11-15
JP33995694 1994-12-28
JP6-339956 1994-12-28
JP7-81705 1995-03-13
JP8170595 1995-03-13
PCT/JP1995/001110 WO1995034559A1 (en) 1994-06-14 1995-06-06 Novel compound, process for producing the same, and antitumor agent

Publications (2)

Publication Number Publication Date
JPWO1995034559A1 JPWO1995034559A1 (ja) 1997-01-28
JP3391796B2 true JP3391796B2 (ja) 2003-03-31

Family

ID=27524935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50192396A Expired - Lifetime JP3391796B2 (ja) 1994-06-14 1995-06-06 新規化合物、その製法および抗腫瘍剤

Country Status (27)

Country Link
US (1) US5817669A (enExample)
EP (1) EP0787726B1 (enExample)
JP (1) JP3391796B2 (enExample)
KR (1) KR100350921B1 (enExample)
CN (1) CN1053668C (enExample)
AT (1) ATE209645T1 (enExample)
AU (1) AU679859B2 (enExample)
BR (1) BR9508037A (enExample)
CA (1) CA2192824C (enExample)
CZ (1) CZ292631B6 (enExample)
DE (1) DE69524251T2 (enExample)
DK (1) DK0787726T3 (enExample)
ES (1) ES2163512T3 (enExample)
FI (1) FI112485B (enExample)
HK (1) HK1000495A1 (enExample)
HU (1) HU220072B (enExample)
MX (1) MX9606331A (enExample)
NO (1) NO307255B1 (enExample)
NZ (1) NZ287139A (enExample)
PL (1) PL181867B1 (enExample)
PT (1) PT787726E (enExample)
RO (1) RO117793B1 (enExample)
RU (1) RU2151770C1 (enExample)
SI (1) SI0787726T1 (enExample)
SK (1) SK281341B6 (enExample)
TW (1) TW319769B (enExample)
WO (1) WO1995034559A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677352B1 (en) * 2001-09-26 2004-01-13 Yamin Wang 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders
US6802423B2 (en) * 2002-02-20 2004-10-12 Trans Global Foods, Inc. Disposable food delivery apparatus
WO2004091627A2 (en) * 2003-04-07 2004-10-28 Cylene Pharmaceuticals, Inc. Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
KR101077755B1 (ko) * 2003-09-10 2011-10-27 교린 세이야꾸 가부시키 가이샤 7-(4-치환-3-시클로프로필아미노메틸-1-피롤리디닐)퀴놀론카르본산 유도체
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
AU2013201203C1 (en) * 2004-03-15 2015-04-23 Sumitomo Dainippon Pharma Co., Ltd. Sns-595 and methods of using the same
MX349188B (es) * 2004-03-15 2017-07-17 Sunesis Pharmaceuticals Inc Sns - 595 y metodos para utilizar el mismo.
RU2405782C2 (ru) * 2004-10-14 2010-12-10 Ф.Хоффманн-Ля Рош Аг Хиназолинилметилентиазолиноны в качестве cdk-1 ингибиторов
EP1805174A1 (en) * 2004-10-14 2007-07-11 F.Hoffmann-La Roche Ag 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity
US7563805B2 (en) * 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
RU2420524C2 (ru) * 2005-05-19 2011-06-10 Дайити Санкио Компани, Лимитед Производные три- или тетра-замещенного-3-аминопирролидина
US20070117770A1 (en) * 2005-08-19 2007-05-24 Cylene Pharmaceuticals, Inc. Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof
AU2013219242C1 (en) * 2005-09-02 2016-09-22 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
RU2428983C2 (ru) * 2005-09-02 2011-09-20 Санесис Фармасьютикалз, Инк. Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
JP5374153B2 (ja) * 2005-09-02 2013-12-25 サネシス ファーマシューティカルズ， インコーポレイテッド 癌の治療のための（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸を使用する方法
CN104873502A (zh) * 2005-09-02 2015-09-02 逊尼希思制药公司 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
AU2006287149B2 (en) * 2005-09-02 2013-05-23 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
KR20080045279A (ko) * 2005-09-14 2008-05-22 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제 저해제로서의5-옥소-5,8-디하이드로-피리도-피리미딘
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
CA2654876A1 (en) * 2006-06-12 2007-12-21 Sunesis Pharmaceuticals, Inc. 1-8-naphthyridine compounds for the treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
ES2556677T3 (es) 2006-08-02 2016-01-19 Sunesis Pharmaceuticals, Inc. Utilización combinada de ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico y citarabina (Ara-C) para el tratamiento de la leucemia
AU2008317400B2 (en) * 2007-10-22 2014-10-02 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino) -1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acid in combination therapy
EP2249831A2 (en) * 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR101765956B1 (ko) 2008-12-31 2017-08-07 선에시스 파마슈티컬스 인코포레이티드 (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
CN104688732A (zh) 2009-02-27 2015-06-10 逊尼希思制药公司 利用sns-595治疗具有降低的brca2活性的癌症对象的方法
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
WO2011056566A2 (en) * 2009-10-26 2011-05-12 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
HRP20161786T1 (hr) 2011-05-13 2017-03-10 Array Biopharma, Inc. Pirolidinil urea, pirolidinil tiourea i pirolidinil gvanidin spojevi kao inhibitori trka kinaze
CN103497186B (zh) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 含有烷氧亚氨基取代的萘啶酮羧酸衍生物及其制备方法
AU2018238079B2 (en) * 2017-03-24 2022-03-03 Wakunaga Pharmaceutical Co., Ltd. Novel pyridone carboxylic acid derivative or salt thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988463A (en) * 1974-05-06 1976-10-26 Merck & Co., Inc. Method of preventing metastasis of H. Ep. No. 3
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
EP0154780B1 (en) * 1984-01-26 1990-04-11 Abbott Laboratories Quinoline antibacterial compounds
JPS61152682A (ja) * 1984-12-27 1986-07-11 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61251667A (ja) * 1985-04-30 1986-11-08 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
PT82752B (pt) * 1985-06-13 1988-12-15 Schering Corp Processo para a preparacao de derivados policiclicos de quinolina, naftiridina e pirazinopiridina
US4851425A (en) * 1985-06-14 1989-07-25 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds and their use as anti-inflammatory and anti-allergic agents
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
JP2704428B2 (ja) * 1988-06-15 1998-01-26 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｙｏｓｈｉｎｏｒｉ Ｙａｍａｓｈｉｔａ，ｅｔ ａｌ．，Ａｎｔｉｔｕｍｏｒ ｑｕｉｎｏｌｏｎｅｓ ｗｉｔｈ ｍａｍｍａｌｉａｎ ｔｏｐｏｉ ｓｏｍｅｒａｓｅ ▲ＩＩ▼ ｍｅｄｉａｔｅｄ ＤＮＡ ｃｌｅａｖａｇｅ ａｃｔｉｖｉｔｙ，Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ，Ｖｏｌ．５２，ｐ．２８１８−２８２２，１９９２

Also Published As

Publication number Publication date
NO965305D0 (no) 1996-12-11
WO1995034559A1 (en) 1995-12-21
EP0787726A1 (en) 1997-08-06
BR9508037A (pt) 1997-09-16
RO117793B1 (ro) 2002-07-30
ES2163512T3 (es) 2002-02-01
CA2192824C (en) 2006-11-07
DK0787726T3 (da) 2002-02-11
CZ364396A3 (en) 1997-06-11
MX9606331A (es) 1997-03-29
EP0787726B1 (en) 2001-11-28
CN1053668C (zh) 2000-06-21
FI965020A7 (fi) 1996-12-16
PL317726A1 (en) 1997-04-28
EP0787726A4 (enExample) 1997-08-06
CA2192824A1 (en) 1995-12-21
CZ292631B6 (cs) 2003-11-12
PT787726E (pt) 2002-04-29
PL181867B1 (pl) 2001-09-28
AU2576795A (en) 1996-01-05
AU679859B2 (en) 1997-07-10
KR100350921B1 (ko) 2002-11-18
DE69524251D1 (de) 2002-01-10
SK157496A3 (en) 1997-08-06
NO307255B1 (no) 2000-03-06
HUT75777A (en) 1997-05-28
ATE209645T1 (de) 2001-12-15
NO965305L (no) 1997-02-04
NZ287139A (en) 1997-07-27
HK1000495A1 (en) 2002-07-19
HU220072B (hu) 2001-10-28
HU9603455D0 (en) 1997-02-28
TW319769B (enExample) 1997-11-11
FI965020A0 (fi) 1996-12-13
CN1158614A (zh) 1997-09-03
RU2151770C1 (ru) 2000-06-27
FI112485B (fi) 2003-12-15
DE69524251T2 (de) 2002-07-11
US5817669A (en) 1998-10-06
SI0787726T1 (en) 2002-04-30
SK281341B6 (sk) 2001-02-12

Similar Documents

Publication Publication Date Title
JP3391796B2 (ja) 新規化合物、その製法および抗腫瘍剤
JPWO1995034559A1 (ja) 新規化合物、その製法および抗腫瘍剤
TWI894413B (zh) 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法
HK1000495B (en) Novel compound, process for producing the same, and antitumor agent
JP4323574B2 (ja) 抗腫瘍剤
JP2546769B2 (ja) キノリン、ナフチリジンおよびピリドベンゾキサジン誘導体
US6316438B1 (en) Fused pyridopyridazine inhibitors of cGMP phosphodiesterase
EA016470B1 (ru) Производные и аналоги n-этилхинолонов и n-этилазахинолонов
HU194561B (en) Process for preparing novel, aminopyrrolidinyl group-substituted 1,8-naphthyridine derivatives and pharmaceuticals comprising such compounds as active substance
KR20130010456A (ko) 신규의 헤테로사이클릭 아크릴아미드 및 약제로서 이의 용도
KR20020094063A (ko) 포스포디에스테라제 저해제로서 유용한 치환된피롤로피리디논 유도체
IE63492B1 (en) A Spiro Compound
KR20160034384A (ko) 인돌 및 피롤의 유도체, 이의 제조 방법 및 이를 함유하는 약제 조성물
JP2025500886A (ja) 大環状ｂｔｋ阻害剤
WO2022199170A1 (zh) 四环类衍生物、其制备方法和其医药上的用途
JP2948660B2 (ja) 新規なピリドンカルボン酸誘導体
CN116600808A (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
WO1992012146A1 (en) Pyridonecarboxylic acid derivative
JP2818198B2 (ja) Ｎ‐（５，６，７，８‐テトラヒドロピリド［２，３‐ｄ］ピリミジン‐６‐イルアルカノイル）グルタミン酸誘導体
JPWO1995021163A1 (ja) ２環性アミノ基で置換されたピリドンカルボン酸誘導体、そのエステルおよびその塩ならびにこれらの中間体たる２環性アミン
JP5079612B2 (ja) 抗腫瘍剤
CN108948003B (zh) 作为mTOR抑制剂的吡嗪并[2,3-c]喹啉-2（1H）-酮类化合物的制备及用途
JPH0873460A (ja) １，８−ナフチリジン化合物および抗腫瘍剤
JP2001181281A (ja) 抗菌剤として有用なキノロン誘導体
JPH1112278A (ja) ピリドンカルボン酸誘導体、そのエステルまたはこれらの塩

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090124

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100124

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110124

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120124

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130124

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140124

Year of fee payment: 11

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term